TRANSFORMING THE TREATMENT OF LIVER DISEASE
Morphocell Technologies is a regenerative medicine company focused on the development and commercialization of stem cell therapies and engineered tissues aimed at treating liver diseases.
An implantable device capable of restoring liver functions in patients with acute and acute-on-chronic liver failure. ReLiver™ELT is already in advanced pre-clinical assessment
An extracorporeal bio-artificial liver device aimed at treating not only patients with acute, but also the tens of millions of patients with chronic liver
An in vitro assay for next-generation drug discovery. As a more representative model of the human liver, ReLiver™Assay helps reducing drug failures in the clinical phases.
Acute Liver Failure
Qualifies as a rare disease with an incidence of <1/100,000 per year
Liver transplantation is the only cure (62% overall survival, <50% for infants
Acute liver failure accounts for >1000 deaths/year in the United States
Up to 80% of patients with ALF could avoid transplantation if temporary replacement of liver functions could be assured while their own liver regenerates.
Through cutting-edge approaches of tissue engineering, Morphocell Technologies is developing revolutionary products targeting currently untreatable liver diseases.
Deaths caused by liver disease worldwide
Acute liver failure: survival rate without liver transplant
+1 (514) 345 4931 ext. 7879
c/o CHU Sainte-Justine Research Center
3175 Ch. Côte-Sainte-Catherine
Montreal, QC, H3T 1C5